Trials / Completed
CompletedNCT05780255
Quality of Life 1y and 2 y After VV-ECMO for COVID-19
Quality of Life 1y and 2 y After VV-ECMO for COVID-19, Measured by the 36-item Short Form Health Survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.
Detailed description
The investigators follow our COVID-19 patients supported by ECMO, we make phone calls or real-life visits to pthe patients to score the quality of life, by using the SF-36. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality , social functioning , role emotional , and mental health. The participants are contacted 3 months, 6months, 1year and 2 years after the ECMO support started for evaluation of the SF-36.
Conditions
- COVID-19 Acute Respiratory Distress Syndrome
- Extracorporeal Membrane Oxygenation Complication
- Quality of Life
- Death
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | VV-ECMO | veno-venous extracorporeal membrane oxygenation |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2023-01-31
- Completion
- 2024-02-01
- First posted
- 2023-03-22
- Last updated
- 2024-04-25
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05780255. Inclusion in this directory is not an endorsement.